Author details

Full Name

John G Doench

Affiliation

ORCID

Career Start Year

1982

Papers

159

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
38048593	Transcriptional control of leukemogenesis by the chromatin reader SGF29.	Blood	2024
36847506	(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.	Cancer Discov	2023
36266353	Base editor scanning charts the DNMT3A activity landscape.	Nature Chemical Biology	2023
38014346	Proteome-wide base editor screens to assess phosphorylation site functionality in high-throughput.		2023
38012416	X-CHIME enables combinatorial, inducible, lineage-specific and sequential knockout of genes in the immune system.		2023
37808733	Genome-wide CRISPR activation screen identifies JADE3 as an antiviral activator of NF-kB.	bioRxiv	2023
37719144	Optimization of Cas12a for multiplexed genome-scale transcriptional activation.		2023
37961518	Modular vector assembly enables rapid assessment of emerging CRISPR technologies.		2023
37873319	Vps18 contributes to phagosome membrane integrity in -infected macrophages.		2023
38052854	Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening.	Nat Commun	2023
36712129	Efficient gene knockout and genetic interactions: the IN4MER CRISPR/Cas12a multiplex knockout platform.	bioRxiv	2023
36894709	Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection.	Nat Genet	2023
36645301	LRP6 Is a Functional Receptor for Attenuated Canine Distemper Virus.		2023
36707513	Chromatin complex dependencies reveal targeting opportunities in leukemia.	Nat Commun	2023
37267104	Scanning mutagenesis of the voltage-gated sodium channel Na<sub>V</sub>1.2 using base editing.	Cell Rep	2023
36811466	Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-Secreted Cytokines.	Cancer Discov	2023
36752207	Developing SHP2-based combination therapy for KRAS-amplified cancer.		2023
36481809	CRISPR screens for functional interrogation of immunity.		2023
36747789	Systematically characterizing the roles of E3-ligase family members in inflammatory responses with massively parallel Perturb-seq.	bioRxiv	2023
36694348	Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.	Neuro Oncol	2023
37310920	DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner.	PLoS Biol	2023
36548402	Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer.	Cancer Res	2023
36739287	ESCRT-dependent STING degradation inhibits steady-state and cGAMP-induced signalling.	Nat Commun	2023
36861834	Protocol for inÂ vivo CRISPR screening using selective CRISPR antigen removal lentiviral vectors.		2023
37228756	Genome-wide CRISPR screening of chondrocyte maturation newly implicates genes in skeletal growth and height-associated GWAS loci.	Cell Genom	2023
36922589	MEN1 mutations mediate clinical resistance to menin inhibition.	Nature	2023
35288574	Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2.	Nature Communications	2022
35775490	Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma.	J Clin Invest	2022
35972292	Selective Polyprotein Processing Determines Norovirus Sensitivity to Trim7.	Journal of Virology	2022
36305736	BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.	Cancer Discov	2022
35513392	Combinatorial GxGxE CRISPR screen identifies SLC25A39 in mitochondrial glutathione transport linking iron homeostasis to OXPHOS.	Nat Commun	2022
36302863	A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer.	Sci Rep	2022
35763665	Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs.	Blood	2022
35505195	Author Correction: DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression.	Nature Microbiology	2022
36008402	Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1.	Nat Commun	2022
35437317	Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.	Nat Cancer	2022
36151395	In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.	Nat Immunol	2022
35879413	Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs.	Nature Genetics	2022
36068235	Accounting for small variations in the tracrRNA sequence improves sgRNA activity predictions for CRISPR screening.	Nature Communications	2022
35793392	In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies.	Blood advances	2022
36566259	A genome-wide CRISPR screen identifies WDFY3 as a regulator of macrophage efferocytosis.		2022
34990589	YAP1 and PRDM14 converge to promote cell survival and tumorigenesis.	Developmental Cell	2022
35332332	Systematic identification of biomarker-driven drug combinations to overcome resistance.	Nat Chem Biol	2022
34933448	High-Throughput CRISPR Screens To Dissect Macrophage- Interactions.	mBio	2021
33707234	CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells.	Cancer Discov	2021
34075371	Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs.		2021
34289345	Control of gasdermin D oligomerization and pyroptosis by the Ragulator-Rag-mTORC1 pathway.	Cell	2021
33953401	Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity.	Nature	2021
33606977	Massively parallel assessment of human variants with base editor screens.	Cell	2021
34031654	Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses.		2021